1. Indonesia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
PT Phapros, Tbk

PT Phapros, Tbk

PEHA.JK
PT Phapros, TbkID flagIndonesia Stock Exchange
230.00
IDR
-28.00
- -
193.20BMarket Cap
PT Phapros, Tbk
PEHA.JK
(Indonesia Stock Exchange)

Recent

price

230.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
560.32
630.66
620.97
688.26
822.91
971.59
1,193.01
1,217.82
1,315.98
1,167.33
1,251.72
1,391.04
1,194.73
886.54
1,120.1
1,144.4
Revenue per Share
77.02
82.33
50.13
53.42
75.01
103.57
149.13
157.51
121.47
57.72
13.18
33.42
9.37
-339.37
33.37
42.04
Basic EPS, GAAP
-10.78
-61.25
- -
- -
- -
- -
- -
-72.42
-38.43
-33.54
-15.85
-18.3
-17.4
-18.09
-8.36
-8.71
Free Cash Flow per Basic Share
34.73
38.2
31.77
36.35
26.96
36.95
51.49
100.86
107.93
82.34
23.23
11.7
15.39
0.09
0.01
- -
Dividend per Share
127.02
182.33
150.13
153.55
175.01
203.57
249.13
257.51
221.47
157.72
113.18
133.42
-2.09
-348.55
-317.07
-315.24
Book Value per Share
401.17
444.83
464.6
484.01
532.84
737.86
830.53
775
812.55
716.75
716.84
753.61
671.82
398.06
440.46
441.51
Tangible Book Value per Share
840
840
840
840
840
840
840
840
840
840
840
840
840
840
840
840
Basic Weighted Avg Shares
470,666
529,753
521,611
578,139
691,247
816,133
1,002,126
1,022,970
1,105,420
980,557
1,051,444
1,168,474
1,003,572
744,695
940,880
961,297
Sales/Revenue/Turnover
17.97
15.93
12.61
12.1
13.43
15.78
18.7
18.97
15.52
6.47
8.46
8.06
6.73
-32.11
9.26
9.71
Operating Margin (%)
5,336
5,402
5,805
1,937
1,897
2,055
3,050
2,936
6,558
13,916
16,844
15,953
14,982
14,945
15,673
16,339
Depreciation Expense
64,696
69,160
42,105
44,875
63,008
87,002
125,266
132,307
102,034
48,488
11,071
28,070
7,871
-285,069
28,031
35,312
Net Income, GAAP
27.22
22.46
24.96
26.52
26.76
28.53
26.89
24.94
21.09
24.06
12.37
33.99
6.15
- -
40.19
39.24
Effective Tax Rate (%)
13.75
13.06
8.07
7.76
9.12
10.66
12.5
12.93
9.23
4.94
1.05
2.4
0.78
-38.28
2.98
3.67
Profit Margin (%)
287,793
286,149
269,958
282,148
330,787
374,172
580,780
37,129
14,944
-59,944
217,100
238,701
104,611
-31,832
361,261
355,711
Working Capital
3,056
2,009
559
134
- -
7,789
209,315
21,062
- -
22,415
263,278
229,543
167,354
278,589
575,701
572,563
LT Debt
339,170
375,627
391,396
407,755
449,720
622,080
701,390
789,798
821,609
740,909
740,977
771,816
676,757
393,122
427,474
428,235
Total Equity
- -
16.01
10.16
9.72
12.31
14.05
16.21
11.34
7.82
2.75
4.75
3.84
4.09
- -
4.7
5.11
Return on Invested Capital (%)
- -
41.14
19.38
21.95
29.41
37.85
38.15
21.37
13.2
10.44
7.8
7.02
7.66
- -
12.46
14.12
Return on Capital (%)
- -
53.23
30.15
35.18
45.66
54.72
65.88
62.18
50.72
30.45
9.73
27.1
7.79
- -
- -
-773.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
301,449
130,957
144,710
LT Borrowings
422,173
575,076
558,040
LT Finance Leases
790
625
14,523
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
840
840
840
Market Capitalization
273,840
252,000
218,400

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
699,140
642,035
678,146
Cash, Cash Equivalents & STI
92,381
120,976
137,181
Accounts Receivable, Net
425,927
349,504
370,631
Inventories
161,695
153,131
145,520
Total Current Liabilities
528,490
280,774
322,435
Payables & Accruals
- -
- -
- -
ST Debt
301,449
130,957
144,710
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.66%
-8.26%
8.74%
Free Cash Flow
- -
-18.4%
-53.76%
Net Income, GAAP
-381.48%
-765.42%
-109.83%
Sales/Revenue/Turnover
4.45%
0.96%
26.34%
Total Cash Common Dividend
-12.28%
-55.68%
-89.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
171,044
196,773
204,367
172,510
744,695
2025
200,671
257,558
225,352
257,299
940,880
2026
221,088
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-35.05
- -
- -
- -
-339.37
2025
-6.84
- -
- -
- -
33.37
2026
1.82
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.09
2025
0.01
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Christina Lake Cannabis Corp. (CLC.CN)
Molecule Holdings Inc. (ERV2.F)
Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
Craftport Cannabis Corp. (BHHKF)
Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
Shineco, Inc. (TYHT)
Business
PT Phapros Tbk (PEHA.JK), a subsidiary of PT Kimia Farma Tbk holding 56.7% of shares, manufactures and markets pharmaceutical products in Indonesia; founded on June 21, 1954, and headquartered in South Jakarta, the company produces over 250 variants including ethical prescription drugs for hospitals and pharmacies such as antidiabetic and immunology therapies; over-the-counter (OTC) medications featuring flagship brands like Antimo (motion sickness tablets and children's syrup), Livron B Plex (cough and cold), Noza, Hemorogard, Bioron, Becefort, Febrinex, and Betafort; branded generic drugs for government institutions and hospitals; toll manufacturing services for other pharmaceutical industries; medical devices including biomaterials like Bonefill Ortho Cube for bone regeneration; and antituberculosis drugs including the Category 1 Daily Dose OAT Package launched in 2025. PT Phapros Tbk operates through segments encompassing OTC, ethical, generic drugs bearing (OGB), and toll-in manufacturing, targeting healthcare institutions, pharmacies, government programs, and international markets; it exports products to Southeast Asia (Cambodia, Philippines, Timor-Leste), Middle East, Latin America (Peru), and Afghanistan, with export performance rising nearly 200% in Q3 2024 and new market entry in Timor-Leste during H1 2024. Recent developments include strategic collaborations with subsidiary PT Lucas Djaja (which acquired 99% of PT Marin Liza Farmasi), universities, and global institutions for innovative dosage forms (chewable tablets, lozenges, powder sachets, ready-to-drink) in travel convenience, cough-cold, antidiabetic, immunology, and biological products; product roadmap expansions in antibiotics, antihypertensives, men's stamina enhancers, and extended-release formulations; a 43% increase in Antimo production ahead of 2024-2025 holidays targeting 9% growth; 25% sales increase and 869% EBITDA growth in H2 2025; achievement of PROPER Green environmental certification in 2025; and celebrations of its 70th anniversary in 2024 emphasizing national health contributions.